A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A61P 1/00 (2006.01) A61P 11/00 (2006.01) A61P 19/00 (2006.01) A61P 31/00 (2006.01) A61P 37/00 (2006.01) C07K 7/22 (2006.01) C07K 16/18 (2006.01)
Patent
CA 2359776
The present invention provides methods for preventing or treating a disease in a subject which is caused by an inflammatory response to a disease or syndrome which is mediated by endogenous substance P. These methods comprise the administration to the subject of a pharmaceutically-effective amount of anti- substance P antibodies, or anti-substance P antibody fragments, such as F(ab)2 fragments, thereby inhibiting the activity of endogenous substance P in the subject. By inhititing the activity of endogenous substance P in the subject, the levels of cytokines produced by T lymphocytes present in the subject are reduced, the signals which direct the inflammatory response to the infection become altered, and the amount of cytokine-induced inflammation becomes reduced. Respiratory syncytial virus is one example of an agent which causes an infection which often results in a disease caused by an inflammatory response to the infection mediated by endogenous substance P. Generally, from about 0.001 mg to about 10 g of anti-substance P antibodies, or anti-substance P antibody fragments, per kilogram of body weight per day are administered to a mammalian subject, with from about 1 mg to about 1000 mg of anti-substance P antibodies, or anti-substance P antibody fragments, per kilogram of body weight per day being preferred.
La présente invention concerne des procédés de prévention ou de traitement d'un trouble chez un sujet ayant une réponse inflammatoire à une maladie ou à un syndrome, ladite réponse inflammatoire étant induite par la substance P endogène. Ces procédés comprennent l'administration au sujet d'une quantité efficace d'un point de vue pharmaceutique d'anticorps anti-substance P, ou de fragments d'anticorps anti-substance P, tels que les fragments F(ab)¿2?, ce qui permet d'inhiber l'activité de la substance P endogène. L'inhibition de l'activité de la substance P endogène chez le sujet provoque la réduction des taux de cytokines produites par les lymphocytes T du sujet, l'altération des signaux qui commandent la réponse inflammatoire à l'infection, ainsi que la réduction de l'inflammation induite par la cytokine. Le virus syncytal respiratoire est un exemple d'agent responsable d'une infection provoquant fréquemment un trouble dû à une réaction inflammatoire à une infection induite par la substance P endogène. En général, on administre à un mammifère une dose d'environ 0,001 mg à environ 10 g d'anticorps anti-substance P, ou de fragments d'anticorps anti-substance P, par kilogramme de poids corporel et par jour, la dose préférée étant comprise entre environ 1 mg et environ 1000 mg d'anticorps anti-substance P, ou de fragments d'anticorps anti-substance P, par kilogramme de poids corporel et par jour.
Anderson Larry J.
Moore Deborah D.
Tripp Ralph A.
Smart & Biggar
The Government Of The United States Of America As Represented By
LandOfFree
Methods for the prevention and treatment of diseases caused... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the prevention and treatment of diseases caused..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the prevention and treatment of diseases caused... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1401002